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Introduction 
Patients presented for surgery for the 
degenerative aortic valve are older and have 
multiple co-morbidities with intermediate or high 
surgical risk profile. Minimally invasive approaches 
and sutureless valves have been developed to 
decrease the operative time and surgical risk in 
those patients [1 – 3]. Sutureless valves offer 
satisfactory hemodynamics and reduce patients’ 
prosthesis mismatch (PPM), in addition to shorter 
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Abstract 
Background: High-risk patients are currently presenting for aortic valve 
replacement (AVR). Sutureless valves may decrease the operative risk in those 
patients. The objective of this study was to compare the short-term and one-year 
follow-up results of the sutureless Perceval valve versus bioprosthetic aortic valve. 
Methods: The data of patients who underwent elective AVR with bioprosthesis 
were collected From March 2012 to March 2017. The patients were divided into two 
groups; group 1 included the patients who had a sutureless aortic valve (Perceval) 
(n= 25; 3.57% of total AVR patients), and group 2 included patients who had 
conventional bioprosthesis (n= 50; 7.1% of total AVR patients).  
Results: The median age of patients in group 1 was 67 years (25th- 75th percentiles; 
64-71), and in group 2 was 66 years (25th- 75th percentiles: 63 to 69). There is no 
significant difference in the patients’ comorbidities between the two groups. The 
median duration of the ischemic time was significantly lower in group 1 (33 (25th- 
75th percentiles: 32- 35) vs. 60.5 (58- 66), respectively; p< 0.001). Perceval valve 
was used more commonly in patients who had minimally invasive AVR (n= 21 (84%) 
in group 1 vs. 11 (22%) in group 2; p<0.001). Postoperative complications were 
comparable between both groups. The early paravalvular leak was non-significantly 
higher in group 1 (12% vs. 2%; p= 0105). The mean postoperative gradient was lower 
in group 1 (7 (7-9) vs. 10 (8-12) mmHg; p<0.001). The changes in valvular gradient 
were not significantly different between both groups (p= 0.5). The hospital stay was 
lower in patients received Perceval valve (Coefficient: -1.3; 95% Cl: -2.3- -0.29; 
p=0.012) 
 Conclusion:  Sutureless aortic valve (Perceval) is a new surgical technique for AVR, 
with potential advantages of reducing cross-clamp time and a subsequent reduction 
in myocardial ischemia, duration of cardiopulmonary bypass, and maintaining 
satisfactory hemodynamic outcomes through reducing patient prosthesis 
mismatch. All these advantages could help in decreasing postoperative hospital 
stay.   
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cardiopulmonary bypass and ischemic time [4 – 
6]. For aortic valve prostheses, PPM is considered 
to be severe when the indexed effective orifice 
area (EOA) is less than 0.65 cm2/m2 [7, 8]. 
The majority of evidence regarding sutureless 
aortic valve replacement was observed from 
limited randomized trials [3]. The International 
Valvular Surgery Study Group (IVSSG), which is the 
largest international collaborative group to 
investigate this technology, has formulated 
sutureless projects in the year 2014 to study the 
cost-effectiveness of this valve [9]. 
There are three commercially available types 
of sutureless aortic prostheses, including 3F 
Enable (Medtronic, Minneapolis, USA), Perceval S 
(Sorin, Saluggia, Italy), and Intuity Elite (Edward 
Lifesciences, Irvine, USA) [4]. The 3F Enable, 
together with Perceval S sutureless prosthesis, 
have nitinol metal frame, which positions the 
valve with no sutures required in the case of 
Perceval S valves or one stitch for Enable 3F 
valves [5].The Intuity valve prosthesis works by a 
different mechanism that is based on a balloon-
expandable stainless steel frame, which is 
implanted with the aid of a balloon-based catheter 
delivery system that expands the frame within 
the aortic annular position [10]. 
The superiority of the Perceval valve over the 
stented bioprosthetic valves is the subject of 
ongoing researches. The objective of this study 
was to compare the sutureless Perceval aortic 
valve to the conventional stented bioprosthetic 
aortic valve. 
Patients and Methods: 
Study design and patients 
This research is a retrospective cohort study 
that was conducted in King Faisal Specialized 
Hospital over five years, starting from March 2012 
till March 2017. The data of patients who 
underwent elective aortic valve replacement 
(AVR) with bioprosthetic valves were collected. 
The patients were divided into two groups; group 
1 included the patients who had a sutureless aortic 
valve (Perceval) (n= 25; 3.57% of total AVR 
patients), and group 2 included patients who had 
conventional tissue bioprosthesis (n= 50; 7.1% of 
total AVR patients). Patients were assigned to 
receive the Perceval valve according to the 
presence of associated comorbidities, which 
increase the operative risk such as renal failure or 
small aortic annulus.  
The data collected included age, sex, and 
comorbidities, such as hypertension, diabetes, 
renal failure, and previous stroke. Operative data 
included the surgical approach, the ischemic, and 
total bypass times. Postoperative data included 
postoperative stroke, patient prosthesis 
mismatch, heart block, early and late paravalvular 
leak, structural valve deterioration (SVD), hospital 
stay, and follow-up echocardiography at an 
interval of 6 months and 1 year postoperatively. 
Data collection was approved by the 
Institutional Review Board at King Faisal 
Specialized and Research Center, and the patient’s 
consent to participate in research was obtained 
during procedure consent.  
Inclusion criteria 
We included patients who had severe 
symptomatic aortic stenosis and aged from 60-80 
years old with preserved contractility (ejection 
fraction ≥50). All operations were performed 
either through a full or mini sternotomy. 
Exclusion criteria 
We excluded patients who had a preoperative 
peripheral vascular disease or end-organ failure 
and patients who had an emergency AVR or 
concomitant procedures. Additionally, we 
excluded patients who had aortic root dilatation 
or AVR through anterolateral thoracotomy.   
Surgical procedures 
The patients were cannulated either through 
the aorta and right atrium or femoro-femoral 
cannulation. After cross-clamping and arresting 
the heart with antegrade cold blood cardioplegia, 
the aortotomy was done in transverse fashion 1 
cm above the sinotubular junction or 3.5 cm 
measured from the outside of the aorta from the 
aortic annulus. The level of the preaortic fat pad 
can be used as a landmark for the aortotomy. 
Three pledged stay sutures were used for better 
exposure. The leaflets were removed, while
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Table 1: Preoperative and operative patients’ data: (Continuous data are presented as median and (25th and 75th 
percentiles) and categorical variable as number and percentage) 
Group 1 (n= 25) Group 2 (n=50) p-value 
Age (years) 67 (64- 71) 66(63-69) 0.604 
Male  20 (80%) 30(60%) 0.083 
Diabetes mellitus 18 (72%) 40(80%) 0.435 
Hypertension 17 (68%) 37(74%) 0.585 
Stroke 2 (8%) 3(6%) >0.99 
Renal failure 1 (4%) 4(8%) 0.659 
Ischemic time (min) 33 (32- 35) 60.5(58-66) < 0.001 
CPB time (min) 61(59-62) 92 (88- 97) < 0.001 
Minimal invasive AVR 21 (84%) 11(22%) < 0.001 
AVR: aortic valve replacement; CPB: cardiopulmonary bypass 
complete decalcification was not required. The 
annulus was sized with a provided valve sizer then 
three double-needle polypropylene sutures were 
passed through the aortic annulus at the 
midpoint between every 2 commissures [11, 12]. 
Each suture was passed through one of the 
eyelets of the prosthesis inflow ring. The valve 
was placed into the aortic annulus with the 
correct positioning of the valve with respect to 
rotational and axial axes [13]. The inflow section 
was released by rotating the knob in a clockwise 
direction. The outflow section was released by 
pulling the safety clip and then withdrawing the 
sheath [13]. Complete contact between the 
inflow ring and the annulus must be assured 
visually. Patency of coronary ostia and leaflet 
coaptation were confirmed. Finally, the guiding 
sutures are removed, and the aortotomy was 
closed, taking care that the sutures were not 
entrapped within the struts [14]. 
Minimal invasive AVR 
The minimal invasive AVR was done through a 
partial J sternotomy at the third to fifth intercostal 
space or a V-shaped approach at the level of the 
second or third intercostal space using the 
sternotomy saw [15, 16]. 
Statistical Analysis 
Continuous variables were presented as the 
50th (median), 25th and 75th percentiles and 
were compared using the Wilcoxon rank-sum test. 
Binary variables were presented as number and 
percent and were compared using Chi-square or 
Fisher exact test when the expected frequency is 
less than 5. Univariable regression analysis was 
used to test the relation between preoperative 
and operative variables and the length of hospital 
stay. The random-effect model was used to test 
the effect on valve type on the changes of the 
postoperative mean pressure gradient. A p-value 
of less than 0.05 was considered statistically 
significant. All analyses were performed using 
Stata 14.2 (Stata Corp- College Station- Texas- 
USA). 
Results 
The median age of patients in group 1 was 67 
years (25th- 75th percentiles; 64-71), and in group 
2 was 66 years (25th- 75th percentiles: 63 to 69). 
There was no significant difference in the 
patients’ comorbidities between the two groups 
(Table 1). The duration of the ischemic time was 
significantly lower in group 1 (P< 0.001). (Table 1) 
Minimal invasive access was used more in 
patients who received Perceval valves (n= 21 
(84%) in group 1 vs. 11 (22%) in group 2; p<0.001) 
(Table 2). There was no significant difference 
between both groups as regards the early 
paravalvular leak (Table 2). Valve-related re-
exploration was higher in group 1 (4% vs. 2%), but 
did not reach a significant level (p˃0.99). 
Postoperative complications are presented in 
Table 2.  
The median postoperative gradient on the 
replaced valve was statistically significantly lower
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Table 2: Postoperative outcomes: (Continuous data are presented as median and (25th and 75th percentiles) and 
categorical variable as number and percentage) 
Group 1 (n=25) Group 2 (n=50) p-value 
Early PVL 3 (12%) 1(2%) 0.105 
Patients prosthesis mismatch 0 4 (8%) 0.294 
HB requiring PM 0 4 (8%) 0.294 
Stroke 0 3 (6%) 0.546 
Valve related re-exploration 1 (4%) 1(4%) >0.99 
Re-exploration for bleeding 2(8%) 4 (8%) >0.99 
Late PVL 2 (8%) 0 0.108 
SVD 0 2 (4%) 0.550 
Mean postoperative PG (mmHg) 7 (7-9) 10 (8- 12) < 0.001 
Hospital stay (days) 7 (6-8) 8 (7-9) < 0.001 
HB: heart block; PG: pressure gradient; PM: pacemaker; PVL: paravalvular leak; SVD: structural valve 
deterioration  
in group 1 compared to group 2 (7 (7-9) vs. 10 (8-
12) mmHg; p<0.001). (Table 2) There was no
statistically significant difference in the 
gradient between groups at follow-up. (Figure 1)  
Figure 1: The mean transvalvular pressure gradient of 
both groups’ early post-operative and at 6 months and 
one-year follow-up. 
The hospital stay period was lower in group 1 
(7 vs. 8 days, P<0.001) (Table 2). Factors affecting 
hospital stay are presented in Table 3, which 
include the bypass and ischemic time, the surgical 
approach, and the type of valve used. 
Discussion 
We found that minimally invasive aortic valve 
procedures using the Perceval sutureless valve 
either through a full or mini-sternotomy approach 
were safe procedures and associated with a 
comparable complication rate to the bioprosthetic 
valves despite the increased risk profile and 
advanced age of our patients.  Moreover, the 
short cross-clamp and bypass times have 
confirmed the safety and feasibility of this valve 
type. As an alternative to bioprosthetic valve, the 
Perceval  sutureless valve avoids passing the 
stitches through the annulus and knotting of the 
sutures to minimize the surgical trauma of the 
aortic annulus and, consequently, reducing both 
the ischemic time and bypass time, and this 
encouraged the surgeons in our center to do more 
minimally invasive cases with Perceval valve. 
Several trials have demonstrated excellent 
clinical and hemodynamic outcomes for patients 
undergoing AVR with the Perceval valves [17 – 
19]. In a study of 32 high-risk patients, Flameng 
and colleagues implanted Perceval valves within 
20 minutes of aortic cross-clamping and reported 
no operative mortality and excellent clinical and 
hemodynamic outcomes [20]. In a study done by 
Folliguet and colleagues presenting the outcomes 
of 208 patients undergoing AVR, the mean cross-
clamp time for isolated AVR was 33 minutes [17]. 
Santarpino and colleagues confirmed these results 
in 51 patients who had undergone a J-shaped 
mini sternotomy [18]. In contrast, Shrestha and 
colleagues described the outcomes of 35 patients 
who had undergone mini sternotomy and 
concluded that the Perceval valve is a technically 
more comfortable alternative, especially in small 
and calcified aortic roots [19].
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Table 3: Univariable regression analysis for preoperative and operative factors affecting the length of hospital stay: 
Variables Coefficient and 95% CI p-value 
Age -0.00074 (-0.063- 0.062) 0.981 
Gender -0.5 (-1.55- 0.55) 0.344 
Diabetes mellitus -0.39 (-1.58- 0.79) 0.508 
Hypertension 0.81 (-0.28- 1.9) 0.143 
Preoperative stroke 0.74 (-1.24- 2.72) 0.457 
Preoperative renal failure 1.17 (-0.8- 3.14) 0.240 
mAVR -1.49 (-2.4- -0.55) 0.002 
Ischemic time 0.056 (0.025- 0.086) 0.001 
CPB time 0.046 (0.019- 0.073) 0.001 
Valve type -1.3 (-2.3- -0.29) 0.012 
CI: confidence interval; CPB: cardiopulmonary bypass; mAVR: minimal invasive aortic valve replacement 
We did not report heart block in the Perceval 
group compared to 8% in the bioprosthesis group; 
this is related to the fact of avoiding extensive 
decalcification of the annulus for implanting the 
Perceval valve [21].The above-mentioned factor 
of avoiding heavily annular decalcification help in 
the reduction of the rate of post-operative stroke 
in the Perceval group, and this goes with what 
was mentioned in the literature by Phan and 
colleagues who found that pooled stroke 
incidences postoperatively appeared to be 
comparable to conventional AVR [22]. The 
current evidence demonstrates acceptable rates 
of neurological events for sutureless valves [3]. 
 Excellent hemodynamic performance 
detected by the statistically significant low mean 
pressure gradient on the Perceval valve was the 
same demonstrated by François Laborde and 
colleagues where  a reduction in the mean 
gradient and peak pressure gradients after using 
Perceval valve was observed to be an average of 
10.2 and 19.3 mmHg postoperatively [23] 
Additionally, this was confirmed by Sadowski and 
coworkers who reported maximal and mean 
gradients of 11.6 and 6.8 mmHg over Perceval 
valve, respectively [24]. All of these advantages of 
Perceval vale lead to a significant reduction in 
hospital stay period in the Perceval group with its 
economic effect on the decline of the medical 
service cost, and it was confirmed in another 
study [25].   
Despite these excellent  results, postoperative 
leak was high in the Perceval group with 
subsequent increase in the rate of valve-related 
re-exploration especially in the early years of the 
study as it was a new technique for us with 
difficult positioning of Perceval valve resulting in 
paravalvular leak and it disappeared in the late 
years of the study after attaining  a good training 
level for the surgeons. This was proved by Phan 
and colleagues in their research where the 
incidence of valve dislocation with the 
paravalvular leak was 2.3%, and this complication 
might be a function of the learning curve involved 
in this innovative new surgical technique, and It is 
possible that paravalvular leak could be reduced 
with experience [22]. A rare complication was 
observed one year later in the Perceval group 
after surgery, which was a paravalvular leak in 
association with a high mean gradient in 2 cases 
(8%). This may be caused by stent fatigue later on, 
and this was reported in the literature [26]. Heart 
block and patients’ prosthesis mismatch were 
more common with the bioprosthetic valves [19, 
27]. 
D’Onofrio and associates performed a 
multicenter analysis of 38 sutureless surgery and 
566 transcatheter aortic valve implantation (TAVI) 
procedures and showed that there was non-
significant lower aortic regurgitation, pacemaker 
implantations and renal replacement therapy in 
the Perceval group [28]. Another study was done 
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by Santarpino, and colleagues expressed higher 
paravalvular leak in the TAVI group compared 
with the Perceval group [13]. Muneretto and 
colleagues compared 53 patients with a sutureless 
valve to 55 patients who underwent TAVI 
procedure and concluded that TAVI was 
associated with a higher rate of pacemaker 
implantations (25.5% vs. 2%) and local peripheral 
vascular complications in the femoral artery 
(14.5% vs. 0%) [14]. 
Study limitations 
The study is limited by the small number of 
patients; however, this is a report of our initial 
experience of using the sutureless aortic valve. 
The small patient’s number limited the 
multivariable analysis to identify independent 
predictors of the outcome. The study is 
observational retrospective research and several 
risk factors may have affected the outcome and 
were unequally distributed between both groups. 
Longer follow-up is required to compare the mean 
gradient across the valve and structural valve 
dysfunction in both groups. 
Conclusion 
Sutureless aortic valve (Perceval) is a new 
surgical technique for AVR, with potential 
advantages of reducing cross-clamp time and a 
subsequent reduction in myocardial ischemia and 
duration of cardiopulmonary bypass, and 
maintaining satisfactory hemodynamic outcomes 
through reducing patient prosthesis mismatch. All 
these advantages could help in decreasing 
postoperative hospital stay.  A learning curve 
involved in this innovative new surgical technique 
is required to be attained by surgeons with gaining 
good experience to reduce its adverse events. 
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